A 3-day-old neonate born to non-consanguineous parents presents with poor feeding, lethargy, and a characteristic musty or 'mousy' odour on the breath. Plasma phenylalanine is 1200 µmol/L (normal <120 µmol/L) and tyrosine is low. Urine shows phenylpyruvate and phenyllactate. What is the most appropriate immediate next step in management?

Explanation

## Clinical Context: Phenylketonuria (PKU) Diagnosis The clinical presentation—musty odour, elevated plasma phenylalanine, and urinary phenylpyruvate—is pathognomonic for **classic phenylketonuria (PKU)**. However, the key phrase is **'most appropriate immediate next step'** in a neonate with suspected but not yet confirmed PKU. ### Why Confirmation is the Next Step **Key Point:** Although the clinical and biochemical picture is highly suggestive of PKU, the immediate next step is **confirmation of diagnosis** rather than empirical treatment initiation, because: 1. **Newborn screening programs** may have false positives or require confirmatory testing before treatment 2. **Plasma amino acid analysis** (quantitative) is the gold standard confirmatory test—it definitively shows elevated phenylalanine and low tyrosine 3. **Repeat testing** rules out transient hyperphenylalanemia (which can occur in premature infants or with liver immaturity) 4. **Differential diagnosis** must exclude benign hyperphenylalaninaemia and other variants before committing to lifelong dietary restriction ### Diagnostic Hierarchy | Test | Timing | Purpose | |------|--------|----------| | Newborn screening (tandem MS) | Day 3–5 | Initial detection | | Plasma amino acid analysis (quantitative) | Immediate (same day) | Confirm elevated Phe, low Tyr | | Urine organic acids | Concurrent | Detect phenylpyruvate, phenyllactate | | Phenylalanine hydroxylase activity (liver biopsy) | If atypical presentation | Distinguish BH₄-responsive PKU | **High-Yield:** In NEET PG, the examiners test whether you know that **confirmation precedes treatment** in neonatal screening—this prevents overtreatment of benign variants and ensures correct diagnosis before lifelong dietary restriction. ### Why Treatment is Deferred **Clinical Pearl:** Sapropterin (BH₄) is only effective in **BH₄-responsive PKU** (30–50% of cases). Before starting it, you must confirm: - Classic PKU (phenylalanine hydroxylase deficiency) vs. BH₄ deficiency - Severity (plasma Phe >1200 µmol/L = classic PKU) Treatment initiation without confirmation risks: - Unnecessary dietary restriction if benign hyperphenylalaninaemia - Wrong drug choice if BH₄ deficiency (requires different management) **Mnemonic: CONFIRM before TREAT** — Confirmation, Organism identification, Repeat testing, Functional studies → then Initiate therapy, Rule out variants, Escalate to specialist, Adjust dosing based on response. ## Management Algorithm ```mermaid flowchart TD A["Suspected PKU: ↑ Phe, musty odour"]:::outcome --> B{"Newborn screening positive?"}:::decision B -->|Yes| C["Plasma amino acid analysis<br/>Urine organic acids"]:::action C --> D{"Phe > 1200 µmol/L?<br/>Tyr low?"}:::decision D -->|Yes| E["Confirm classic PKU<br/>Test for BH₄ responsiveness"]:::action D -->|No| F["Benign hyperphenylalaninaemia<br/>Observe, no treatment"]:::outcome E --> G{"BH₄ responsive?"}:::decision G -->|Yes| H["Start sapropterin<br/>+ dietary Phe restriction"]:::action G -->|No| I["Start Phe-restricted diet<br/>+ medical foods"]:::action H --> J["Monitor Phe levels<br/>Neurodevelopmental follow-up"]:::outcome I --> J ``` **Tip:** In the exam, if the stem says 'suspected' or 'presumed' diagnosis, the next step is **confirmation** (repeat test, imaging, or specialist assessment), not empirical treatment.